

## Test Update

November 01, 2010

Effective immediately, the T315I FRET assay is discontinued.

A new, allele-specific T315I direct sequencing assay is in development with an expected implementation date for the fourth quarter of this year. In the interim, we are pleased to offer T315I analysis with our current BCR-ABL Kinase Domain Sequencing assay.

The BCR-ABL Kinase Domain Sequencing assay detects mutations between amino acids 30 and 510 including the kinase domain SH3, SH2 and regions 3' to the ABL kinase domain. Over 40 amino acid substitution in the tyrosine kinase domain of BCR-ABL (including T315I) can be detected with this direct sequencing assay. Any mutation found in this sequencing assay will be included on the patient report.

We thank you for choosing **MolecularMD** and look forward to your continued support.

*For additional information please contact Client Services at 503-459-4974, extension 2.*

